Empowered Funds LLC Acquires Shares of 87,905 Halozyme Therapeutics, Inc. $HALO

Empowered Funds LLC bought a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 87,905 shares of the biopharmaceutical company’s stock, valued at approximately $6,880,000.

A number of other institutional investors also recently modified their holdings of the stock. Horizon Investment Services LLC acquired a new position in Halozyme Therapeutics in the 2nd quarter worth about $2,254,000. Mizuho Markets Americas LLC raised its stake in shares of Halozyme Therapeutics by 270.8% during the 4th quarter. Mizuho Markets Americas LLC now owns 1,268,673 shares of the biopharmaceutical company’s stock worth $85,382,000 after purchasing an additional 926,526 shares in the last quarter. Chase Investment Counsel Corp acquired a new stake in shares of Halozyme Therapeutics during the 2nd quarter valued at about $2,035,000. Great Lakes Advisors LLC acquired a new stake in shares of Halozyme Therapeutics during the 2nd quarter valued at about $2,821,000. Finally, Aurora Investment Counsel bought a new stake in shares of Halozyme Therapeutics in the 2nd quarter valued at approximately $1,427,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ HALO opened at $105.35 on Monday. The business’s 50-day simple moving average is $87.01 and its 200-day simple moving average is $74.74. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. Halozyme Therapeutics, Inc. has a 52 week low of $61.22 and a 52 week high of $109.66. The firm has a market cap of $11.96 billion, a price-to-earnings ratio of 31.45, a P/E/G ratio of 0.42 and a beta of 0.85.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping the consensus estimate of $1.79 by $0.49. The firm had revenue of $481.00 million during the quarter, compared to analyst estimates of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The company’s revenue for the quarter was up 47.7% on a year-over-year basis. During the same period in the previous year, the company earned $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, equities research analysts expect that Halozyme Therapeutics, Inc. will post 7.77 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on HALO shares. TD Cowen increased their price objective on Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a “buy” rating in a report on Friday, August 7th. UBS Group reissued a “buy” rating and issued a $90.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Friday, August 7th. Weiss Ratings downgraded shares of Halozyme Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, August 14th. Finally, Wall Street Zen raised shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Nine research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $91.20.

Insider Activity

In other news, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $104.18, for a total value of $2,083,600.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $79,987,320.40. The trade was a 2.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the business’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $75.00, for a total transaction of $547,800.00. Following the completion of the sale, the director owned 14,462 shares of the company’s stock, valued at $1,084,650. The trade was a 33.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 42,478 shares of company stock valued at $3,767,304 over the last 90 days. 2.50% of the stock is currently owned by company insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.